We're pleased to share that
@TheLancet has published results from Capricor's Phase 3 HOPE-3 trial evaluating Deramiocel in
#Duchenne muscular dystrophy.
The independent peer-reviewed publication validates the trial's design, statistical methodology and findings. HOPE-3 met its primary endpoint, with Deramiocel slowing upper limb function decline by 54 percent versus placebo (PUL 2.0, p=0.03) and demonstrating a clinically meaningful cardiac benefit.
Read more here:
thelancet.com/journals/lance…
We are grateful to the patients, families, investigators and study teams who made this research possible.